inclusion criteria: 1. hospitalized with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult \> / = 18 years of age at time of enrollment. 4. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva \< / = 14 days prior to randomization. 5. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). 6. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 7. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. hospitalized with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult \> / = 18 years of age at time of enrollment. 4. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva \< / = 14 days prior to randomization. 5. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). 6. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 7. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: hospitalized with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. male or non-pregnant female adult > / = 18 years of age at time of enrollment. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva < / = 14 days prior to randomization. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: hospitalized with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. male or non-pregnant female adult > / = 18 years of age at time of enrollment. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva < / = 14 days prior to randomization. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. hospitalized with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 4. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva < / = 14 days prior to randomization. 5. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). 6. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 7. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. hospitalized with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures and understands and agrees to comply with planned study procedures. 3. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 4. illness of any duration and has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay (e.g. naat, antigen test) in any respiratory specimen or saliva < / = 14 days prior to randomization. 5. within the 7 days prior to randomization requiring new use of supplemental oxygen (or increased oxygen requirement if on chronic oxygen) and requires at the time of randomization low or high flow oxygen devices or use of non-invasive mechanical ventilation (ordinal scale category 5 or 6). 6. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 7. agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.